In this study, the deletion of Smad4 and PTEN genes in mice was associated with rapid and invasive squamous cell carcinoma formation in the forestomach, modeling human esophageal cancer progression.
1461 citations
,
March 2004 in “Annals of oncology” This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.
25 citations
,
January 2017 in “Steroids” This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.
23 citations
,
January 2014 in “International Journal of Biological Sciences” This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
5 citations
,
November 2024 in “Naunyn-Schmiedeberg s Archives of Pharmacology” This review highlighted the role of microRNAs (miRNAs) in gouty arthritis, emphasizing their potential influence on disease progression through immune and inflammatory regulation, and their prospective use in diagnosis, prognosis, and therapy.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.
March 2026 in “Folia Histochemica et Cytobiologica” This review highlights LTBP1 as a critical integrator in disease processes, showing its dual role in cancer progression and suppression, its pathological influence in fibrosis, and its contribution to various disorders, suggesting its potential as a biomarker and therapeutic target.
February 2026 in “Oncology Reviews” This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.
January 2025 in “Iraqi Journal of Science” This study found that variations in the genes PDCD4, miR-21, and miR-449b may significantly influence breast cancer progression, with higher PDCD4 serum levels linked to increased breastfeeding.
October 2024 in “Frontiers in Oncology” This review examines the potential of K18 as a diagnostic and prognostic marker in epithelial-derived tumors, highlighting its specific expression in tumor tissues and interaction with proteins involved in tumor progression, without reporting new clinical findings.
This case report describes a rare instance of pilomatricoma, a benign tumor of the hair follicle, accompanied by striae distensae on a young man's flank, emphasizing the uniqueness of this presentation for timely diagnosis and care due to its potential for malignant transformation.
January 2024 in “Wiadomości Lekarskie” This review highlights that AI-based echocardiography in cardiology can enhance diagnostic precision, automation, and therapeutic strategy development, but also presents challenges like diagnostic errors and high costs, indicating a cautious yet promising progression in its adoption.
April 2022 in “Research Square (Research Square)” This study established the R-7 dermal papilla cell line, which retained essential characteristics of primary cells without undergoing malignant transformation, suggesting its potential for future hair research.
36 citations
,
November 2000 in “Journal of the American Academy of Dermatology” This case study describes a unique patient with dermatomyositis who exhibited features of pityriasis rubra pilaris and porokeratosis, suggesting markers for malignancy warranting thorough investigation and monitoring.
14 citations
,
December 2010 in “Seminars in Oncology” This review discusses the diagnostic challenges of androgen and estrogen-secreting adrenal tumors and highlights that the presence of metastases is the most reliable indicator of malignancy; it reports no new clinical findings.
13 citations
,
August 2020 in “Mayo Clinic proceedings” In this study, women with lichen planopilaris were found to have high rates of thyroid disease, depression, and anxiety, and about half experienced slowed or stabilized disease progression with treatment.
29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.
December 2023 in “Juan Cuevas eBooks” This source describes the fourth volume of the "Guía de Procedimientos en Cirugía Plástica Reconstructiva" as an essential, expert-compiled reference detailing the latest advanced techniques in reconstructive plastic surgery for surgeons, residents, and professionals in the field.
April 2023 in “International journal of science and research” In this study, PRP treatment improved hair loss in 40 female patients with female pattern alopecia, with most progressing to better grades of hair coverage after 6 months, while only minor pain was occasionally reported as an adverse effect.
January 2024 in “Wiadomości Lekarskie” This source explores the integration of artificial intelligence in medicine, addressing critical questions about readiness among doctors and patients, regulatory measures, ethical issues, economic impact, legal considerations, and the potential replacement of physicians, based on current publications and over 40 years of professional experience.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that p21 is much more highly expressed in normal melanocytes compared to melanoma cells, suggesting a potential target for preventing melanoma progression through cell cycle repair processes.
November 2025 in “Cancer Cell International” This study provides a detailed cellular atlas of cutaneous squamous cell carcinoma, indicating that different fibroblast subtypes play roles in tumor progression and suppression, with potential biomarkers identified for HPV-related tumor growth.
May 2018 in “European Journal of Dermatology” The first Japanese family with Marie Unna hereditary hypotrichosis showed hair condition improvement in a child and highlighted the risk of misdiagnosis.
192 citations
,
June 1992 in “Journal of The American Academy of Dermatology” Hair loss can cause low self-esteem, anxiety, and depression in men.
17 citations
,
July 2016 in “The Prostate” This study found that metformin is inversely associated with serum PSA levels in a dose-dependent manner, suggesting further research is needed on its potential impact on prostate cancer progression.
January 2025 in “Dermatology Review” The authors report a rare case of trichilemmal carcinoma in the thigh of a 71-year-old, emphasizing the importance of complete surgical excision to prevent recurrence and support patient prognosis.
71 citations
,
September 2007 in “Cancer” This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.
14 citations
,
April 2017 in “American Journal of Transplantation” This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.
9 citations
,
October 2025 in “MedComm” This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.